JP Morgan maintains Zai Lab at Overweight, raises price target to $37 from $36
JP Morgan kept Zai Lab at Overweight, raising its price target to $37 from $36, a 2.8% increase. This implies a 113.3% upside from the Nov 19 close of $17.35.
Zai Lab Ltd
Zai Lab is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for conditions in oncology, immunology, neuroscience and infectious disease. It serves patients through commercial products and a pipeline of in-licensed and internally developed candidates. Zai Lab has a substantial presence in Greater China and the United States. The company has seven commercial programs with products launched in one or more Greater China territories. Its products include ZEJULA, VYVGART and VYVGART Hytrulo, NUZYRA, OPTUNE, QINLOCK, XACDURO and AUGTYRO. Zai Lab sells and promotes products through commercial teams covering sales, marketing, medical affairs, market access and distributor management; it also works with partners on commercialization and product development. Its research and development activities include internal discovery, clinical development and collaborations with biopharmaceutical companies and external research partners. Zai Lab is headquartered in Shanghai.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
JP Morgan kept Zai Lab at Overweight, raising its price target to $37 from $36, a 2.8% increase. This implies a 113.3% upside from the Nov 19 close of $17.35.
Zai Lab Limited announced that five of its commercial medicines, including two new drugs, KarXT and VYVGART Hytrulo, were added to China's National Reimbursement Drug List (NRDL) for 2026. The list will take effect on January 1, 2027, potentially impacting the company's sales and market access in China.
Zai Lab Limited announced that five of its medicines, including two new products, KarXT and VYVGART Hytrulo, have been added to China’s 2026 National Reimbursement Drug List. The list will take effect on January 1, 2027, according to the company.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning ZLAB (Zai Lab Ltd). Coverage has skewed bullish: 5 bullish, 0 neutral, and 0 bearish.
Recent ZLAB coverage spans financial news, technology and regulation.
In the last 30 days, ZLAB insiders filed 1 SEC Form 4 transaction — 1 purchase ($33K) and no sales. The most active reporter was GAYNOR RICHARD with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Street valuation support likely modestly positive, but this is an analyst target change rather than a new company event.
The NRDL inclusion is likely to boost Zai Lab's Chinese sales pipeline and improve revenue outlook.
Inclusion on the reimbursement list may boost sales and margins for the two products, supporting Zai Lab's revenue outlook.
Positive early‑stage data may boost investor confidence and lift the stock.
Earnings show modest revenue growth but a widening loss; however, strong early trial data could spark upside on pipeline expectations.
AlphAI scores every news story that mentions ZLAB with an AI model for sentiment and relevance, and aggregates insider trades from Zai Lab Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
JP Morgan kept Zai Lab at Overweight, raising its price target to $37 from $36, a 2.8% increase. This implies a 113.3% upside from the Nov 19 close of $17.35.
Zai Lab Limited announced that five of its commercial medicines, including two new drugs, KarXT and VYVGART Hytrulo, were added to China's National Reimbursement Drug List (NRDL) for 2026. The list will take effect on January 1, 2027, potentially impacting the company's sales and market access in China.
Zai Lab Limited announced that five of its medicines, including two new products, KarXT and VYVGART Hytrulo, have been added to China’s 2026 National Reimbursement Drug List. The list will take effect on January 1, 2027, according to the company.
Zai Lab (ZLAB, 9688) reported phase 1 trial results for ZL-1503, a bispecific antibody for atopic dermatitis. A single 200 mg dose showed 90% inhibition of a key biomarker and reduced inflammation markers. No serious adverse events were reported. The trial is ongoing, with patient data expected in 2027. Results were presented at a medical conference.
Zai Lab reported Q3 2026 revenue of $116.1M, up 2% sequentially. The company anticipates key milestones in 2027, including Phase 3 studies for zocilurtatug pelitecan (zoci) in SCLC and potential FDA submissions. ZL-1503, an IL-13/IL-31Rα bispecific antibody, is advancing toward clinical milestones. Zai Lab raised $250M in a private placement to fund pipeline development.
Zai Lab's (ZLAB) drug zocilurtatug pelitecan (zoci) showed 81.8% response rate and 81.9% 6-month progression-free survival in a Phase 1b trial for extensive-stage small cell lung cancer. The combination with atezolizumab was well-tolerated. A Phase 3 trial is planned for 2026. Zai Lab will discuss the data in an investor call.
Zai Lab Ltd (ZLAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. © 2026. Zai Lab. All Rights Reserved.NASDAQ:ZLAB | HKEX:9688 Advancing First- and Best-in- Class Therapies in Oncology and Immunology October 2026 Forward-Looking Statements 2 Forward-Looking Statements This presentation contains forward-looking statements, including statements r
Zai Lab (ZLAB) will present Phase 1/1b trial data for ZL-1503, an experimental eczema treatment, at ACAAI 2026. The data, from healthy volunteers, includes pharmacokinetic and pharmacodynamic results. ZL-1503 targets IL-13 and IL-31, aiming to provide rapid itch relief and reduce inflammation. An investor conference call is scheduled for November 13, 2026.
Cantor Fitzgerald reiterated an Overweight rating and $37 price target for Zai Lab (ZLAB), citing potential for its DLL3 ADC, zocilurtatug, in small cell lung cancer. The stock is up 45% year-to-date. Zai Lab's Q2 earnings beat expectations with $106.3M revenue and adjusted EPS of -$0.05. Analysts maintain a Strong Buy consensus with price targets ranging from $24.25 to $50.
Zai Lab (ZLAB) will present global clinical trial data on zocilurtatug pelitecan (zoci) for first-line extensive-stage small cell lung cancer (ES-SCLC) at ESMO Congress 2026. The trial evaluates zoci in combination with atezolizumab with or without carboplatin. An investor call is scheduled for October 23, 2026, to discuss the data and future plans. Zai Lab highlights zoci's potential as a backbone ADC in ES-SCLC treatment.